Johnson & Johnson said Wednesday it would release more information soon on the question of boosting its one-shot coronavirus vaccine.
US officials said earlier Wednesday they were making plans to offer booster doses of vaccine starting in September to people who got Moderna’s and Pfizer’s two-dose shots, pending authorization by the US Food and Drug Administration and the US Centers for Disease Control and Prevention,
J&J’s Janssen vaccine became available months after the Pfizer and Moderna vaccines were deployed, and federal officials said there wasn’t enough data yet to say anything to the millions of Americans who got the Janssen shot.
The company said it’s working on it.
“We are engaging with the U.S. FDA, CDC and other health authorities and will share new data shortly regarding boosting with the Johnson & Johnson Covid-19 vaccine,” J&J said in a statement.
“In July, Johnson & Johnson shared data demonstrating that our single-shot Covid-19 vaccine generated strong, persistent immune activity against the rapidly spreading Delta variant and other highly prevalent SARS-CoV-2 viral variants. Interim results from a Phase 1/2a study published in the New England Journal of Medicine also showed that the durability of the immune response was strong, with no waning for at least eight months, the length of time that had been evaluated to date,” it said. “Ensuring long-term and durable protection against hospitalization and death are critical in curbing the Covid-19 pandemic.”